Compare FBIZ & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | VNDA |
|---|---|---|
| Founded | 1909 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.9M | 474.0M |
| IPO Year | 2012 | 2005 |
| Metric | FBIZ | VNDA |
|---|---|---|
| Price | $52.52 | $8.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $65.00 | $14.90 |
| AVG Volume (30 Days) | 23.0K | ★ 3.6M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 14.23 | N/A |
| EPS | ★ 5.94 | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.47 | $38.67 |
| P/E Ratio | $8.87 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $42.18 | $3.81 |
| 52 Week High | $60.54 | $9.91 |
| Indicator | FBIZ | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 56.73 |
| Support Level | $46.71 | $7.39 |
| Resistance Level | $53.17 | $9.35 |
| Average True Range (ATR) | 1.68 | 0.55 |
| MACD | -0.25 | 0.09 |
| Stochastic Oscillator | 31.57 | 50.03 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.